title: Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
abstract: OBJECTIVE
  To evaluate the effect of certolizumab pegol (CZP) on productivity outside and within the home, and on participation in family, social and leisure activities in adult patients with psoriatic arthritis (PsA).
  
  
  METHODS
  RAPID-PsA (NCT01087788) is a phase 3, double-blind, placebo-controlled trial. 409 patients with active PsA were randomised 1:1:1 to placebo, CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS) assessed the impact of PsA on paid work and household productivity, and participation in social activities during the preceding month. WPS responses were compared between treatment arms using a non-parametric bootstrap-t method.
  
  
  RESULTS
  At baseline, 56.6%, 60.1% and 61.5% of placebo, CZP 200 mg Q2W and CZP 400 mg Q4W patients were employed. By week 24, employed CZP patients reported an average of 1.0-1.8 and 3.0-3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05). Within the home, by week 24, CZP patients reported an average of 3.0-3.5 household work days gained per month versus 1.0 day for placebo (p<0.05). CZP patients also reported fewer days with reduced household productivity or days lost for participation in family, social and leisure activities. Improvements with CZP were seen as early as week 4 and continued to week 24.
  
  
  CONCLUSIONS
  CZP treatment significantly improved productivity at paid work and within the home, and resulted in greater participation in social activities for PsA patients.
  
  
  BACKGROUND
  NCT01087788.
authors.affiliation: Division of Rheumatology, Allergy and Immunology, UCSD, San Diego, California, USA.
authors.forename: A
authors.initials: A
authors.lastname: Kavanaugh
authors.affiliation: Division of Health Care & Outcomes Research, Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Gladman
authors.affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands.
authors.forename: D
authors.initials: D
authors.lastname: van der Heijde
authors.affiliation: UCB Pharma, Brussels, Belgium.
authors.forename: O
authors.initials: O
authors.lastname: Purcaru
authors.affiliation: Swedish Medical Center and University of Washington, Seattle, Washington, USA.
authors.forename: P
authors.initials: P
authors.lastname: Mease
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000068582:Certolizumab Pegol; D004311:Double-Blind Method; D004526:Efficiency; D004651:Employment; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007899:Leisure Activities; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D018582:Sick Leave; D058992:Social Participation; D016896:Treatment Outcome; D014937:Work
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol